Lindahl advises sell-side in connection with the transfer of Olink Proteomics to Summa Equity. Olink Proteomics provides a world-leading technology for human protein biomarker discovery. Summa Equity focuses on investments in companies that contribute to the solution of global challenges.
Lindahl's team consisted of Mattias Prage (responsible partner), Anna Romell Stenmark, Hugo Norlén, Disa Almqvist, Therese Norenäs and Chia Mohtadi.
